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ABSTRACT 64 
 65 
The clustering of different types of B-cell malignancies in families raises the possibility of 66 
shared aetiology. To examine this, we performed cross-trait linkage disequilibrium (LD)-67 
score regression of multiple myeloma (MM) and chronic lymphocytic leukaemia (CLL) 68 
genome-wide association study (GWAS) datasets, totalling 11 734 cases and 29 468 69 
controls. A significant genetic correlation between these two B-cell malignancies was 70 
shown (Rg=0.4, P=0.0046). Furthermore, four of the 45 known CLL risk loci were shown to 71 
associate with MM risk and five of the 23 known MM risk loci associate with CLL risk. By 72 
integrating eQTL, Hi-C and ChIP-seq data, we show that these pleiotropic risk loci are 73 
enriched for B-cell regulatory elements and implicate B-cell developmental genes. These 74 
data identify shared biological pathways influencing the development of CLL and, MM and 75 
further our understanding of the aetiological basis of these B-cell malignancies. 76 
  77 
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INTRODUCTION 78 
 79 
Chronic lymphocytic leukaemia (CLL) and multiple myeloma (MM) are both B-cell 80 
malignancies, which arise from the clonal expansion of progenitor cells at different stages of 81 
B-cell maturity (1-3).  Evidence for inherited predisposition to CLL and MM comes from the 82 
6 and 2-fold increased risk of respective diseases seen in relatives of patients(4).  83 
 84 
Recent genome-wide association studies (GWAS) have transformed our understanding of 85 
genetic susceptibility to the B-cell malignancies, identifying 45 CLL (5-8) and 23 MM risk loci 86 
(9-12). Furthermore, statistical modelling of GWAS data indicates that common genetic 87 
variation is likely to account for 34% of CLL and 15% of MM heritability (6, 13). 88 
Epidemiological observations on familial cancer risks across the different B-cell malignancies 89 
suggest an element of shared inherited susceptibility, especially between CLL and MM (4).  90 
 91 
Linkage disequilibrium (LD) score regression is a method which exploits the feature of a test 92 
statistic for a given single nucleotide polymorphism (SNP), whereby that test statistic will 93 
incorporate the effects of correlated SNPs (14). Conventional LD score regression regresses 94 
trait χ² statistics against the LD score for a given SNP, with the coefficient of the regression 95 
line providing an estimate of trait heritability. This method can be modified by instead 96 
regressing the product of SNP Z scores from two traits against the SNP LD score, with the 97 
slope providing an estimate of genetic covariance between the two traits (15). This method 98 
can be applied to summary statistics, is not biased by sample overlap and does not require 99 
multiple traits to be measured for each individual.  100 
 101 
By analysis of GWAS data for MM and CLL and applying cross-trait LD score regression we 102 
have been able to demonstrate a positive genetic correlation between CLL and MM. We find 103 
evidence of shared genetic susceptibility at 10 known risk loci and by integrating promoter 104 
capture Hi-C (PCHi-C) data, ChIP-seq and expression data we provide insight into the shared 105 
biological basis of CLL and MM.   106 
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METHODS 107 
GWAS datasets 108 
The data from six previously reported MM GWAS (9-12) are summarized in Supplementary 109 
Table 1. All these studies were based on individuals of European ancestry and comprised: 110 
Oncoarray-GWAS (878 cases 7,054 controls) UK-GWAS (2,282 cases, 5,197 controls), 111 
Swedish-GWAS (1,714 cases, 10,391 controls), German-GWAS (1,508 cases, 2,107 controls), 112 
Netherlands-GWAS (555 cases, 2,669 controls) and US-GWAS (780 cases, 1,857 controls).  113 
The data from three previously reported CLL GWAS (8-12) are summarized in 114 
Supplementary Table 2. All these studies were based on individuals of European ancestry 115 
and comprised: CLL UK1 (505 cases and 2,698 controls), CLL UK2 (1,236 cases and 2,501 116 
controls) and CLL US (2,174 cases and 2,682 controls).   117 
 118 
Ethics 119 
Collection of patient samples and associated clinico-pathological information was 120 
undertaken with written informed consent and relevant ethical review board approval at 121 
respective study centres in accordance with the tenets of the Declaration of Helsinki.  122 
 123 
Specifically for the Myeloma-IX trial by the Medical Research Council (MRC) Leukaemia Data 124 
Monitoring and Ethics committee (MREC 02/8/95, ISRCTN68454111), the Myeloma-XI trial 125 
by the Oxfordshire Research Ethics Committee (MREC 17/09/09, ISRCTN49407852), 126 
HOVON65/GMMG-HD4 (ISRCTN 644552890; METC 13/01/2015), HOVON87/NMSG18 127 
(EudraCTnr 2007-004007-34, METC 20/11/2008), HOVON95/EMN02 (EudraCTnr 2009-128 
017903-28, METC 04/11/10), University of Heidelberg Ethical Commission (229/2003, S-129 
337/2009, AFmu-119/2010), University of Arkansas for Medical Sciences Institutional 130 
Review Board (IRB 202077), Lund University Ethical Review Board (2013/54), the Norwegian 131 
REK 2014/97, and the Danish Ethical Review Board (no: H-16032570). 132 
 133 
Specifically, the centres for UK-CLL1 and UK-CLL2 are: UK Multi-Research Ethics Committee 134 
(MREC 99/1/082); GEC: Mayo Clinic Institutional Review Board, Duke University Institutional 135 
Review Board, University of Utah, University of Texas MD Anderson Cancer Center 136 
Institutional Review Board, National Cancer Institute, ATBC: NCI Special Studies Institutional 137 
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Review Board, BCCA: UBC BC Cancer Agency Research Ethics Board, CPS-II: American Cancer 138 
Society, ENGELA: IRB00003888—Comite d’ Evaluation Ethique de l’Inserm IRB #1, EPIC: 139 
Imperial College London, EpiLymph: International Agency for Research on Cancer, HPFS: 140 
Harvard School of Public Health (HSPH) Institutional Review Board, Iowa-Mayo SPORE: 141 
University of Iowa Institutional Review Board, Italian GxE: Comitato Etico Azienda 142 
Ospedaliero Universitaria di Cagliari, Mayo Clinic Case–Control: Mayo Clinic Institutional 143 
Review Board, MCCS: Cancer Council Victoria’s Human Research Ethics Committee, MSKCC: 144 
Memorial Sloan-Kettering Cancer Center Institutional Review Board, NCI-SEER (NCI Special 145 
Studies Institutional Review Board), NHS: Partners Human Research Committee, Brigham 146 
and Women’s Hospital, NSW: NSW Cancer Council Ethics Committee, NYU-WHS: New York 147 
University School of Medicine Institutional Review Board, PLCO: (NCI Special Studies 148 
Institutional Review Board), SCALE: Scientific Ethics Committee for the Capital Region of 149 
Denmark, SCALE: Regional Ethical Review Board in Stockholm (Section 4) IRB#5, Utah: 150 
University of Utah Institutional Review Board, UCSF and UCSF2: University of California San 151 
Francisco Committee on Human Research, Women’s Health Initiative (WHI): Fred 152 
Hutchinson Cancer Research Center and Yale: Human Investigation Committee, Yale 153 
University School of Medicine. Informed consent was obtained from all participants. 154 
 155 
The diagnosis of MM (ICD-10 C90.0) in all cases was established in accordance with World 156 
Health Organization guidelines. All samples from patients for genotyping were obtained 157 
before treatment or at presentation. The diagnosis of CLL (ICD-10-CM C91.10, ICD-O 158 
M9823/3 and 9670/3) was established in accordance with the International Workshop on 159 
Chronic Lymphocytic Leukaemia guidelines. 160 
 161 
Quality control 162 
Standard quality-control measures were applied to the GWAS (16). Specifically, individuals 163 
with low SNP call rate (<95%) as well as individuals evaluated to be of non-European 164 
ancestry (using the HapMap version 2 CEU, JPT/CHB and YRI populations as a reference) 165 
were excluded. For apparent first-degree relative pairs, we excluded the control from a 166 
case-control pair; otherwise, we excluded the individual with the lower call rate. SNPs with a 167 
call rate <95% were excluded as were those with a MAF <0.01 or displaying significant 168 
deviation from Hardy–Weinberg equilibrium (P < 10−5). GWAS data were imputed to >10 169 
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million SNPs using IMPUTE2 v4 (for CLL) and IMPUTE2 v2.3 (for MM) software in 170 
conjunction with a merged reference panel consisting of data from 1000 Genomes Project 171 
(17) (phase 1 integrated release 3 March 2012) and UK10K (18). Genotypes were aligned to 172 
the positive strand in both imputation and genotyping. We imposed predefined thresholds 173 
for imputation quality to retain potential risk variants with MAF >0.01 for validation. Poorly 174 
imputed SNPs with an information measure <0.80 were excluded. Tests of association 175 
between imputed SNPs and MM were performed under an additive model in 176 
SNPTESTv2.5(19). The adequacy of the case–control matching and possibility of differential 177 
genotyping of cases and controls was evaluated using a Q-Q plot of test statistics. The 178 
inflation λ was based on the 90% least-significant SNPs and assessment of λ1000. Details of 179 
SNP QC are provided in in Supplementary Table 3 and 4. Four principal components, 180 
generated using common SNPs, were included to limit the effects of cryptic population 181 
stratification in the US-CLL dataset. Eigenvectors for the GWAS data sets were inferred using 182 
smartpca (part of EIGENSOFT) by merging cases and controls with Phase II HapMap samples. 183 
 184 
Meta-analysis 185 
Meta-analyses were performed using the fixed-effects inverse-variance method using META 186 
v1.6 (20). Cochran's Q-statistic to test for heterogeneity and the I2 statistic to quantify the 187 
proportion of the total variation due to heterogeneity was calculated. 188 
 189 
LD score regression 190 
To investigate genetic correlation between MM and CLL we implemented cross-trait LD 191 
score regression by Bulik-Sullivan et al (15). Using summary statistics from the GWAS meta-192 
analysis we implemented filters as recommended by the authors (15). Specifically, filtering 193 
SNPs to INFO >0.9, MAF >0.01, and harmonizing to Hap Map3 SNPs with 1000 Genomes EUR 194 
MAF >0.05, removing indels and structural variants, removing strand-ambiguous SNPs and 195 
removing SNPs where alleles did not match those in 1000 Genomes. This was performed by 196 
running the munge-sumstats.pr script included with ldsc. We ran ldsc.py, part of the ldsc 197 
package, excluding the HLA region. We report heritability estimates on the observed scale. 198 
There is no distinction between observed and liability scale genetic correlation for 199 
case/control traits (15). 200 
 201 
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Shared risk loci 202 
To identify pleiotropic risk loci, that is genetic loci that influence two traits, we identified 203 
SNPs previously reported to be associated with each disease at genome-wide significance (P 204 
< 5 × 10-8), as well as highly correlated variants (r2 > 0.8) at the 45 and 23 known risk loci for 205 
CLL and MM respectively. Within these correlated variant sets at each locus, we determined 206 
how many of the CLL susceptibility loci were associated with MM at region-wide significance 207 
after Bonferroni correction for multiple testing (i.e. Padj < 0.05/45). We then repeated the 208 
process, examining MM susceptibility SNPs in CLL, applying a significance level of Padj < 209 
0.05/23. A full list of results is summarized in Supplementary Data File 1 and 2. 210 
 211 
Partitioned heritability 212 
A variation of LD score regression, namely stratified LD score regression, can be used to 213 
partition heritability according to different genomic categories. For both MM and CLL we 214 
applied stratified LD score regression across the baseline model used in Finucane et al (21). 215 
We plotted the enrichment of functional categories for each disease- this is defined as 216 
proportion heritability divided by the total heritability. We excluded from our plot additional 217 
flanking regions around each functional category, which authors designed to allow 218 
observation of enrichment of SNP heritability in intermediary regions. A plot of the results is 219 
found in Supplementary Figure 1.   220 
 221 
Variant set enrichment 222 
To examine enrichment in specific histone mark binding across shared risk loci, we adapted 223 
the method of Cowper-Sal lari et al. (22). Briefly, for each risk locus, a region of strong LD 224 
(defined as r2 > 0.8 and D′ > 0.8) was determined, and these SNPs were considered the 225 
associated variant set (AVS). Publically available ChIP-seq data for 6 histone marks from 226 
naïve B-cells was downloaded from Blueprint Epigenome Project (23). For each mark, the 227 
overlap of the SNPs in the AVS and the binding sites was assessed to generate a mapping 228 
tally. A null distribution was produced by randomly selecting SNPs with the same 229 
characteristics as the risk-associated SNPs, and the null mapping tally calculated. This 230 
process was repeated 10,000 times, and P-values calculated as the proportion of 231 
permutations where null mapping tally was greater or equal to the AVS mapping tally. An 232 
enrichment score was calculated by normalizing the tallies to the median of the null 233 
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distribution. Thus, the enrichment score is the number of standard deviations of the AVS 234 
mapping tally from the median of the null distribution tallies. An enrichment plot for naïve B 235 
cells is shown in Supplementary Figure 2. 236 
 237 
Cell type specific analyses 238 
We considered chromatin mark overlap enrichment for genome-wide significant loci in 239 
different cell types using the methodology of Trynka et al (24).This approach scores GWAS 240 
SNPs based on proximity to chromatin mark and fold-enrichment of respective chromatin 241 
mark, assessing significance using a tissue-specific permutation method. We obtained chip-242 
seq data for H3K4me3 from primary blood cells and CLL samples downloaded from 243 
Blueprint Epigenome project (23). In addition, we included in our analysis 4 MM cell lines- 244 
KMS11, JJN3, MM1-S and L363 processed as previously described (25). A heat map of results 245 
is shown in Supplementary Figure 3.   246 
 247 
eQTL 248 
eQTL analyses were performed using publicly available  whole blood data downloaded from 249 
GTeX (26). The relationship between SNP genotype and gene expression we carried out 250 
using Summary-data-based Mendelian Randomization (SMR) analysis as per Zhu et al (27). 251 
Briefly, if bxy is the effect size of x (gene expression) on y (slope of y regressed on the genetic 252 
value of x), bzx is the effect of z on x, and bzy be the effect of z on y, bxy (bzy/bzx) is the effect 253 
of x on y. To distinguish pleiotropy from linkage where the top associated cis-eQTL is in LD 254 
with two causal variants, one affecting gene expression the other affecting trait we tested 255 
for heterogeneity in dependent instruments (HEIDI), using multiple SNPs in each cis-eQTL 256 
region. Under the hypothesis of pleiotropy bxy values for SNPs in LD with the causal variant 257 
should be identical. For each probe that passed significance threshold for the SMR test, we 258 
tested the heterogeneity in the bxy values estimated for multiple SNPs in the cis-eQTL region 259 
using HEIDI. 260 
 261 
GWAS summary statistics files were generated from the meta-analysis. For the disease 262 
discovery GWAS, we set a threshold for the SMR test of PSMR < 2.5 × 10-5 corresponding to a 263 
Bonferroni correction for the number of probes which demonstrated an association in the 264 
SMR test. For all genes passing this threshold we generated plots of the eQTL and GWAS 265 
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associations at the locus, as well as plots of GWAS and eQTL effect sizes (i.e. input for the 266 
HEIDI heterogeneity test). HEIDI test P-values < 0.05 were considered as reflective of 267 
heterogeneity. This threshold is, however, conservative for gene discovery because it 268 
retains fewer genes than when correcting for multiple testing. SMR plots for significant 269 
eQTLs are shown in Supplementary Figure 4-5 and a summary of results are shown in 270 
Supplementary Table 5.  271 
 272 
Data availability 273 
SNP genotyping data that support the findings of this study have been deposited in Gene 274 
Expression Omnibus with accession codes GSE21349, GSE19784, GSE24080, GSE2658 and 275 
GSE15695; in the European Genome-phenome Archive (EGA) with accession code 276 
EGAS00000000001; in the European Bioinformatics Institute (Part of the European 277 
Molecular Biology Laboratory) (EMBL-EBI) with accession code E-MTAB-362 and E-TABM-278 
1138; and in the database of Genotypes and Phenotypes (dbGaP) with accession code 279 
phs000207.v1.p1. The remaining data are contained within the paper and Supplementary 280 
Files or available from the author upon request. Naïve B-cell HiC data used in this work is 281 
publicly available from Blueprint Blueprint Epigenome Project [https://osf.io/u8tzp/]. ChIP-282 
seq data for H3K27ac, H3K4Me1, H3K27Me3, H3K9Me3, H3K36Me3 and H3K27Me3 from 283 
naïve B-cells is publicly available and was obtained from Blueprint Epigenome Project 284 
[http://www.blueprint-epigenome.eu/].  285 
  286 
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RESULTS 287 
 288 
Genetic correlation and heritability 289 
We performed cross trait LD-score regression using summary statistics from two recent 290 
GWAS meta-analyses based on 7,717 MM cases and 21,587 controls and 4,017 CLL cases 291 
and 7,881 controls (Figure 1, Supplementary Table 1-4). While these datasets have been 292 
previously subject to quality control (QC) (5-7, 9-11) for the current analysis we 293 
implemented additional filtering steps as per Bulik-Sullivan et al (15), resulting in 1,055,728 294 
harmonized SNPs between the two datasets. Heritability estimates from cross-trait LD score 295 
regression of 9.2 (±1.8%) and 22 (±5.9%) were comparable with previous estimates for MM 296 
(13) and CLL (6). LD-score regression revealed a significant positive genetic correlation 297 
between MM and CLL with an Rg value of 0.44 (P = 4.6×10-3).  298 
 299 
Identification of pleiotropic risk loci  300 
We identified SNPs previously reported to be associated with each disease at genome-wide 301 
significance (P < 5 × 10-8), as well as highly correlated variants (r2 > 0.8) at the 45 and 23 302 
known risk loci for CLL and MM respectively. To identify pleiotropic risk loci, that is genetic 303 
loci that influence two traits, we determined how many of the CLL susceptibility loci were 304 
associated with MM at region-wide significance after Bonferroni correction for multiple 305 
testing (i.e. Padj < 0.05/45). We then repeated the process, examining MM susceptibility SNPs 306 
in CLL, applying a significance level of Padj < 0.05/23. Of the 45 CLL risk loci, four were 307 
associated with MM (Padj < 0.0011) while, of 23 MM risk loci, five were significantly 308 
associated in CLL (Padj < 0.0022) (Table 1, Figure 2). Correlated SNPs (r2 > 0.8) at 3q26.2 are 309 
associated with both CLL and MM at genome-wide significance (Figure 2), bringing the total 310 
number of pleiotropic loci to 10.  311 
 312 
Biological inference 313 
Trynka et al. have recently shown that chromatin marks highlighting active regulatory 314 
regions overlap with phenotype-associated variants in a cell-type specific manner (24). Since 315 
H3K4me3 was shown to be the most phenotypically cell-type specific chromatin mark, we 316 
examined cell-type specificity of the 10 pleiotropic risk loci by analysing H3K4me3 chromatin 317 
marks in normal haematopoietic cells and CLL patient samples from Blueprint, and de novo 318 
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data on KMS11, MM1S, JJN3 and L363 MM cell lines. Cell types showing the strongest 319 
enrichment of risk SNPs at H3K4me3 marks included naïve B-cells and CD38-B cells. Notably, 320 
variants at 2q31.1, 6p25.3, 8q24.21, 16q23.1 and 22q13.33 were enriched for H3K4me3 in 321 
naïve B-cells (Supplementary Figure 3).  322 
 323 
Most GWAS signals map to non-coding regions of the genome (28, 29)  and influence gene 324 
expression through chromatin looping interactions (30, 31). Application of partitioned 325 
heritability analysis, stratifying across 53 genomic categories demonstrated enrichment of 326 
CLL and MM heritability in functional elements of the genome, in particular FANTOM5 327 
enhancers (CLL and MM)  transcription start sites (CLL) and 5’ untranslated region and 328 
coding regions (MM)  (Supplementary Figure 1). Furthermore, we found significant 329 
enrichment of SNPs in the shared loci within regions of active chromatin, as indicated by the 330 
presence of H3K27ac and H3K4Me3 marks in naïve B-cells, supporting the principle that 331 
SNPs in shared loci influence risk through regulatory effects (Supplementary Figure 2). To 332 
identify target genes we analysed PCHi-C data on naïve B-cells from Blueprint (23). We also 333 
sought to gain insight into the possible biological mechanisms for associations by 334 
performing an expression quantitative trait locus (eQTL) analysis using mRNA expression 335 
data on blood from GTEx. Applying Summary data-based Mendelian Randomization (SMR) 336 
methodology, we tested for pleiotropy between GWAS signal and cis-eQTL for genes to 337 
identify a causal relationship. Broadly, our analysis of the shared loci groups them into those 338 
which act on a B-cell regulation and differentiation and those which underpin the distinctive 339 
biology of cancer; specifically, loci relating to genome instability, angiogenesis and 340 
dysregulated apoptosis (Supplementary Table 6). 341 
 342 
Of the shared loci, three were related to B-cell regulation. This included composite evidence 343 
at 10q23.31, from looping interactions in naïve B-cells and correlation in GWAS effect size 344 
and expression, which provide evidence for two candidate genes ACTA2, encoding smooth 345 
muscle (α)-2 actin, a protein involved in cell movement and contraction of muscles (32) and 346 
FAS, a member of the TNF-receptor superfamily. FAS, has a central role in regulating the 347 
immune response through apoptosis of B-cells (33, 34). At 2q31.1, looping interactions 348 
implicated transcription factor SP3, which has been shown to influence expression of 349 
  Went et al 
13 
 
germinal centre genes, (35, 36). Variants at 6p25.3 reside in the 3’UTR of IRF4, which has an 350 
established role in B-cell regulation (37, 38) and MM oncogenesis (39, 40).  351 
 352 
Three of the 10 loci contain genes with roles in maintenance of genomic stability. 353 
Specifically, evidence from expression and PCHi-C data implicated RFWD3 at 16q23.1. This 354 
gene encodes an E3 ubiquitin-protein ligase, which has been shown to promote progression 355 
to late stage homologous recombination through ubiquitination and timely removal of 356 
RAD51 and RPA at sites of DNA damage (41) and is necessary for replication fork restart 357 
(42). Variants in this locus demonstrated enrichment of H3K4me3 marks in two samples of 358 
naïve B-cells, which represents a plausible cell of disease origin. rs58618031 (7q31.33) maps 359 
5′ of POT1, the protection of telomeres 1 gene, which is part of the shelterin complex and 360 
functions to maintain chromosomal stability (43, 44). Variant rs1317082 at 3q26.2 is located 361 
proximal to TERC, a gene which has been shown to influence telomere length (45). 362 
Additionally, we observed looping interactions to a number of genes at 3q26.2 including 363 
SEC62, which has been proposed as a cancer biomarker (46-49). Intriguingly, variants at 364 
3q26.2 this locus have been implicated in colorectal (50), thyroid (51) and bladder (52) 365 
cancer. 366 
 367 
Several genes were implicated at 22q13.33 by looping interactions for SCO2, LMF2, ODF3B, 368 
TYMP/ECGF1, NCAPH2, SYCE3 and ARSA, with TYMP/ECGF1 and SCO2 demonstrating 369 
evidence of correlation in GWAS and eQTL effect size, albeit not significant after multiple 370 
testing (PSMR = 2.38×10-4 and 3.19×10-4). Variants within this locus were enriched in 371 
H3K4me3 chromatin marks in both CD38- B cells and inflammatory macrophages. TYMP 372 
(alias ECGF1) encodes thymidine phosphorylase, which is often overexpressed in tumours 373 
and has been linked to angiogenesis (53, 54).  A detailed study on this gene has implicated 374 
TYMP in the development of lytic bone lesions in MM, via a mechanism involving activation 375 
of PI3K/Akt signalling and increased DNMT3A expression resulting in hypermethylation of 376 
RUNX2, osterix, and IRF8(55). Furthermore, SCO2 (synthesis of cytochrome c oxidase), also 377 
mapping to this locus, has been implicated in the development of breast (56, 57), gastric 378 
(58) and leukemia (59), through glucose metabolism reprogramming (60), a hallmark of 379 
cancer (61). Tumour suppressor, p53, regulates metabolic pathways, p53-transactivated 380 
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TP53-induced glycolysis (TIGAR), and regulation of apoptosis in part through SCO2 (57, 58, 381 
60).   382 
 383 
Finally, while these data were indifferent to decipher 8q24.21, this locus has also been 384 
shown to harbour risk SNPs for other cancers which localize within distinct LD blocks and 385 
likely reflect tissue-specific effects on cancer risk through regulation of MYC (29). 386 
 387 
  388 
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DISCUSSION 389 
 390 
Our analysis provides evidence of a genetic correlation between MM and CLL. Furthermore, 391 
we have identified shared genetic susceptibility at 10 known risk loci. While requiring 392 
biological validation, integration of data from PCHi-C, chromatin mark enrichment and eQTL 393 
at shared loci has provided insight into how these loci may confer susceptibility to both CLL 394 
and MM. Applying a working hypothesis that the loci may act in pleiotropic fashion, we 395 
selected relevant cells representing a common tissue of disease origin; namely naïve B-cells.  396 
 397 
A significant genetic correlation between MM and CLL, as well as the discovery of risk loci 398 
shared between them, supports epidemiological data demonstrating elevated familial risks 399 
between these B-cell malignancies (4). Furthermore, the shared loci we identified could be 400 
broadly grouped into those containing genes related to B-cell regulation and differentiation 401 
and those containing genes involved in angiogenesis, genome stability and apoptosis, 402 
supporting the tenet that these alleles can influence aetiology of either disease. With the 403 
expansion of GWAS of the B-cell malignancies, more detailed characterisation of common 404 
underlying risk alleles and affected pathways can inform the biology of B-cell oncogenesis. 405 
 406 
 407 
 408 
 409 
 410 
 411 
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TABLE AND FIGURE LEGENDS 733 
 734 
Table 1: Risk loci demonstrating association of alleles at respective loci in both chronic 735 
lymphocytic leukaemia (CLL) and multiple myeloma (MM). – indicates SNP not present in 736 
filtered data.  737 
 738 
Figure 1: Schematic outlining the processing of datasets used in the genetic correlation. 739 
 740 
Figure 2: Overlap of loci in multiple myeloma and chronic lymphocytic leukaemia.  741 
*correlated variants at 3q26.2 had been previously published as genome wide significant in 742 
each dataset prior to this analysis. 743 
 744 
 745 
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TABLES 749 
 750 
Locus Discovery  
GWAS 
Sentinel  
Variant 
Correlated 
Variant 
Position  
(hg19) 
Risk allele Odds Ratio P 
CLL MM CLL MM CLL MM 
2q31.1 MM rs4325816   174,808,899 T T 1.11 1.12 2.0 ×10
-3 6.4 ×10-7 
      rs72919402 174,750,200 T - 1.13 - 4.6 ×10
-4 - 
3q26.2 
MM  
& CLL 
rs1317082 
 
169,497,585 A A 1.20 1.19 7.1 ×10-8 2.2 ×10-16 
rs3821383 169,489,946 A A 1.20 1.18 4.2 ×10-8 4.5×10-15 
6p25.3 CLL rs872071   411,064 G G 1.37 1.10 2.8 ×10
-27 7.5 ×10-7 
      rs1050976 408,079 T T 1.37 1.10 1.9×10
-27 3.7×10-7 
6p22.3 MM rs34229995 15,244,018 G G 1.37 1.36 8.5 ×10
-3 5.6 ×10-8 
rs13197919 15,282,334 T T 1.35 1.32 1.3 ×10-3 3.42 ×10-7 
7q31.33 MM rs58618031   124,583,896 T T 1.15 1.11 3.2 ×10
-5 1.7 ×10-7 
      rs59294613 124,554,267 C - 1.16 - 4.4 ×10
-6 - 
8q24.21 MM rs1948915 128,222,421 C C 1.17 1.15 7.6 ×10
-7 2.5 ×10-12 
- - - - - - - - 
10q23.31 CLL rs6586163   90,752,018 A A 1.28 1.06 1.1 ×10
-16 1.8 ×10-3 
      rs7082101 90,741,615 - C - 1.06 - 8.2 ×10
-4 
11q23.2 CLL rs11601504 113,526,853 C C 1.20 1.09 2.3 ×10
-5 8.5 ×10-4 
- - - - - - - - 
16q23.1 MM rs7193541   74,664,743 T T 1.12 1.12 1.0 ×10
-4 3.7 ×10-10 
  CLL   - - - - - - - - 
22q13.33 rs140522 50,971,266 T T 1.17 1.08 3.7 ×10
-7 1.2 ×10-4 
      - - - - - - - - 
 751 
Table 1: Risk loci demonstrating enrichment of alleles at respective loci in both chronic 752 
lymphocytic leukaemia (CLL) and multiple myeloma (MM). – indicates SNP not present in 753 
filtered data. 754 
 755 


